FACT Cellular Therapy & CAR-T Accreditation — Frequently Asked Questions

What is FACT accreditation for cellular therapy and CAR-T programs?

FACT accreditation is a peer-reviewed quality standard administered by the Foundation for the Accreditation of Cellular Therapy (FACT) — a non-profit organization founded in 1996 by ISCT and ASTCT. FACT verifies that a clinical program meets evidence-based standards for the collection, processing, and administration of cellular therapy products across four program types: Hematopoietic Cellular Therapy (HCT), Immune Effector Cells (IEC/CAR-T), Cord Blood Banking, and Collection for Further Manufacturing.

Current accreditation numbers (as of February 2, 2026): 277 Cellular Therapy Entities globally, 178 IEC (CAR-T) programs, 49 cord blood banks, approximately 86% market penetration among established US transplant centers. The global cell and gene therapy market: $8.94 billion (2025), projected $45.24 billion by 2035 at 17.60% CAGR.

Do CAR-T manufacturers require FACT accreditation to access their products?

Yes, in practice. The major commercial CAR-T manufacturers require or strongly recommend FACT IEC accreditation:

• Novartis / Kymriah — requires authorized treatment center status, which requires FACT IEC accreditation
• Kite-Gilead / Yescarta — requires authorized treatment center qualification including FACT accreditation
• Bristol Myers Squibb / Breyanzi — requires certified treatment center status
• Janssen / Carvykti — requires authorized treatment center certification

Without FACT IEC accreditation, hospitals cannot order or administer these products — each priced at $375,000 to $450,000+ per infusion. The access barrier is contractual, not regulatory: manufacturers impose it as a condition of product distribution agreements.

Does Medicare require FACT accreditation for CAR-T therapy reimbursement?

Yes. CMS covers FDA-approved CAR-T therapies when administered at FACT-accredited programs. A hospital that administers CAR-T without FACT accreditation cannot bill Medicare for the therapy. This creates direct revenue risk on top of the manufacturer access restriction — the same program that cannot order the product without FACT accreditation also cannot bill for it if it somehow obtained the product.

Blue Cross Blue Shield Blue Distinction Center for Transplants requires full FACT accreditation including IEC Standards compliance. Loss of Blue Distinction affects payer network access and reimbursement rates for the full transplant and cellular therapy service line.

What is the difference between FACT HCT accreditation and FACT IEC (CAR-T) accreditation?

FACT HCT (Hematopoietic Cellular Therapy) covers traditional bone marrow and peripheral blood stem cell transplantation. FACT IEC (Immune Effector Cells) covers programs administering FDA-approved CAR-T therapies. The standards are separate — different documents, different Crosswalk requirements, different minimum volume thresholds, different inspection criteria.

Academic transplant centers typically hold both. Community oncology programs typically pursue IEC only, entering cellular therapy through CAR-T rather than traditional transplantation. The minimum volume requirements differ by accreditation type; IHS assesses eligibility at engagement inception for each program type.

What is the FACT accreditation process and how long does it take?

Initial FACT accreditation takes 12 to 24 months. The phases:

1. Eligibility and Registration (Month 1) — confirm minimum volume requirements; sign BAA; pay registration fee
2. Compliance Crosswalk and document development (Months 1–12) — SOP library, QMP, Facility Grids, personnel documentation, Written Agreements, IT validation documentation
3. Desk review and RFI management (Months 12–14) — FACT Coordinator reviews uploaded documentation; IHS manages all RFI responses
4. On-site inspection (Months 14–18) — volunteer peer inspectors audit chain-of-custody, observe procedures, interview staff, evaluate facilities
5. CAPA response and accreditation award (Months 18–24) — IHS authors CAPA responses; accreditation granted upon FACT Committee acceptance

Annual Report required at Year 1 anniversary. Renewal report due 14 months before 3-year expiration.

What are the most common deficiencies found during FACT inspections?

The eight most consistently cited FACT deficiency areas:

1. Traceability / Chain of Custody — broken documentation chain from collection through manufacturing through administration
2. Written Agreements with manufacturers — missing or inadequately reviewed agreements with commercial CAR-T manufacturers
3. QMP execution — Quality Management Plan written but never executed; no management reviews, no quality indicators tracked, no corrective action
4. Adverse event reporting — inadequate CRS and neurotoxicity event reporting systems within mandated timeframes
5. SOP discrepancies — staff using procedures that differ from published SOPs
6. Training and competency assessments — missing documented annual competency assessments for all clinical and laboratory staff
7. ISBT 128 labeling — incomplete implementation, heightened under 9th Edition for further manufacturing products
8. Electronic systems validation — EMR and LIMS not formally validated (IQ/OQ/PQ) prior to use

What is the difference between FACT and AABB accreditation for cellular therapy?

FACT and AABB have different scopes, inspection models, and cycle lengths:

For programs administering commercial CAR-T therapies, FACT is required. AABB standards compliance is required for blood bank operations that support cellular therapy programs. IHS advises on the combined FACT + AABB compliance framework for programs needing both.

Can a community cancer center get FACT accredited for CAR-T?

Yes. FACT's Community IEC Standards provide a fit-for-purpose accreditation pathway specifically designed for community oncology settings. The standards recognize operational differences between academic transplant centers and community cancer programs while maintaining equivalent patient safety requirements.

As CAR-T moves to second-line standard of care, community hospitals must build FACT programs from scratch. The demand is real and growing — hundreds of community oncology networks will need FACT Community IEC accreditation as CAR-T becomes standard rather than salvage therapy. IHS specializes in community CAR-T program development: clinical protocol documentation, nursing competency programs, FACT Crosswalk for Community IEC standards, and written agreements with commercial manufacturers.

How long is FACT accreditation valid before renewal?

FACT accreditation is valid for 3 years. Key milestones:

• Year 1 anniversary — Comprehensive Annual Report due: clinical outcomes, personnel changes, continued compliance evidence
• Month 22 of 3-year cycle — Full renewal report must be submitted (14 months before 3-year expiration) to initiate re-inspection
• Year 3 — Full on-site re-inspection; accreditation renewed for another 3-year cycle

The 14-month renewal submission deadline is the most commonly missed milestone. IHS tracks cycle milestones for all active clients and initiates renewal preparation at Month 22, not Month 34.

What quality management system requirements does FACT require?

FACT requires a documented and executed Quality Management Plan (QMP) covering:

• Quality philosophy and organizational structure
• Management review protocols — documented reviews at defined intervals with quality data analysis
• Audit schedules — internal quality audits of all program components
• Quality indicators — tracked metrics with defined thresholds and corrective action triggers
• CAPA system — documented corrective and preventive actions for all quality findings
• Document control — version control, SOP review cycles, obsolete document management
• Adverse event reporting — defined systems for recognizing, investigating, and reporting CRS and neurotoxicity events

The QMP must be executed — FACT inspectors verify execution through documented management review records and evidence of corrective actions taken in response to quality data. Writing a QMP without executing it is the most common FACT citation.

What is a FACT Compliance Crosswalk and how is it built?

A FACT Compliance Crosswalk is a systematic mapping of every FACT standard to the program's internal policies, SOPs, and quality documents that demonstrate compliance. It is the central document FACT reviews before scheduling an on-site inspection. Building a complete Crosswalk for a CAR-T IEC program spans six facility components: Clinical Facility, Collection Facility (apheresis), Cell Processing Laboratory, Quality Management, Information Technology, and Personnel.

IHS builds the Crosswalk as the core deliverable of every FACT engagement — starting at engagement inception and managing it as a living document through desk review, RFI responses, and inspection. The Crosswalk methodology IHS uses is identical to the AccreditNet document management approach developed for URAC accreditation — adapted to FACT's standards architecture.

What changed in the FACT-JACIE 9th Edition Standards (effective February 2026)?

The FACT-JACIE 9th Edition (effective February 2, 2026) made three major structural changes from the 8th Edition:

1. Consolidated Collection Standards — peripheral blood, bone marrow, and TIL collection standards merged into a single Collection section with unified chain-of-custody requirements. Programs collecting multiple modalities must update their SOP libraries to the consolidated framework.
2. New REMS Standards — ASTCT 80/20 Task Force recommendations formally incorporated: programs administering REMS-covered CAR-T products must now demonstrate REMS compliance as part of the FACT survey.
3. ISBT 128 Labeling for Further Manufacturing — products collected for pharma manufacturing contracts require ISBT 128 labeling from collection under the 9th Edition. Programs upgrading apheresis centers for pharma contracts must implement ISBT 128 labeling before their next survey.

All surveys after February 2, 2026 reference the 9th Edition. AABB separately updated its Cellular Therapy Services standards to the 12th Edition, effective July 1, 2025.

What is the relationship between FACT accreditation and the FDA REMS program?

FDA REMS and FACT are complementary but distinct. REMS is a manufacturer-specific FDA safety framework specifying healthcare provider training requirements for high-risk products — CAR-T manufacturers must implement REMS programs as a condition of FDA approval. FACT accreditation is a program-level quality standard. The FACT 9th Edition (effective February 2, 2026) formally integrates REMS compliance: programs administering REMS-covered products must now demonstrate REMS program compliance as part of the FACT survey. This closes a gap that previously required programs to manage FACT accreditation and REMS compliance as separate tracks. IHS manages both as a unified workstream.

How does Blue Cross Blue Shield use FACT accreditation for CAR-T reimbursement?

Blue Cross Blue Shield Blue Distinction Center for Transplants requires full FACT accreditation — both HCT Standards compliance and IEC Standards compliance — for Blue Distinction Center designation. Blue Distinction Center designation affects: payer network tier placement, reimbursement rates for transplant and CAR-T services, patient steerage from BCBS plans to Blue Distinction Centers, and institutional revenue from BCBS-insured patients. Programs that lose Blue Distinction Center status face reimbursement rate changes and potential patient volume loss from BCBS plans. FACT IEC accreditation is a direct prerequisite for maintaining Blue Distinction Center for Transplants status.

What internal staff resources are needed to pursue and maintain FACT accreditation?

FACT requires:

• Quality Manager — can be fractional for smaller programs; manages QMP execution, tracks quality indicators, coordinates audits
• Medical Director — ultimate clinical accountability for all FACT standards; must be actively engaged in collegial review and QMP oversight
• Cell Processing Laboratory Director — responsible for processing facility compliance, equipment validation, and laboratory quality documentation

Programs performing approximately 70 cellular transplants per year require approximately 1.5 dedicated FTEs in the cell processing laboratory for quality and operational management. IHS minimizes the burden on internal staff by handling Crosswalk development, SOP drafting, mock inspection preparation, and annual report management.

How much does FACT accreditation consulting cost?

Comprehensive end-to-end consulting engagements for new programs: $150,000 to $350,000+, covering eligibility assessment, full Crosswalk development, SOP library creation, QMP development, mock inspection, and CAPA management. Targeted engagements are scoped separately:

• 9th Edition transition gap analysis and Crosswalk update — scoped based on existing documentation maturity
• Mock inspection only — scoped based on program size and facility count
• Annual report support — scoped based on program complexity

FACT's own accreditation fees are not publicly disclosed — custom-quoted by FACT based on scope, site count, and patient volume. FACT Applicant Workshop: $595 early registration, $650 regular. IHS provides a fixed-scope proposal after an initial readiness assessment.